Education
About Us
Working with TipRanks
Follow Us
Catalyst Pharmaceutical Partners (CPRX)
:CPRX
Catalyst Pharma (CPRX) Ownership Overview
6.26% Insiders
17.71% Mutual Funds
16.76% Other Institutional Investors
24.35% ETFs
34.93% Public Companies and
Individual Investors
The ownership structure of Catalyst Pharma (CPRX) stock is a mix of institutional, retail, and individual investors. Approximately 58.81% of the company’s stock is owned by Institutional Investors, 6.26% is owned by Insiders, and 34.93% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
| Mar 07, 2025 | Gary Ingenito Chief Med. & Reg. Officer | xxxxxxxxxxxxx | $4894610 |
| Mar 05, 2025 | Brian Elsbernd Chief Compliance/legal Officer | xxxxxxxxxxxxx | $1446933 |
| Mar 05, 2025 | xxxxxxxxxxxxx | $696382 | |
| Dec 11, 2024 | Steve Miller Chief Op. & Scientific Officer | xxxxxxxxxxxxx | $1096000 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2024 | xxxxxxxxxxxxx | $519767 | |
| Dec 31, 2024 | xxxxxxxxxxxxx | $812949 | |
| Dec 31, 2024 | xxxxxxxxxxxxx | $1812496 | |
| Dec 31, 2024 | xxxxxxxxxxxxx | $5279463 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 13,133,261 | Institution | 10.81% | 276,061,146 | |
| 6,813,992 | Institution | 5.61% | 143,230,112 | |
| 5,228,965 | Institution | 4.31% | 109,912,844 | |
| 4,481,702 | Insider | 3.69% | 94,205,376 | |
| 3,133,011 | Institution | 2.58% | 65,855,891 | |
| 3,044,784 | Institution | 2.51% | 64,001,360 | |
| 2,363,752 | Institution | 1.95% | 49,686,067 | |
| 1,864,351 | Institution | 1.54% | 39,188,658 | |
| 1,748,269 | Institution | 1.44% | 36,748,614 | |
| 1,228,762 | Institution | 1.01% | 25,828,577 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 5,228,965 | Institution | 4.31% | 109,912,844 | |
| 1,748,269 | Institution | 1.44% | 36,748,614 | |
| 1,228,762 | Institution | 1.01% | 25,828,577 | |
| 1,143,825 | Institution | 0.94% | 24,043,202 | |
| 1,126,568 | Institution | 0.93% | 23,680,459 | |
| 965,117 | Institution | 0.79% | 20,286,759 | |
| 899,586 | Institution | 0.74% | 18,909,298 | |
| 782,498 | Institution | 0.64% | 16,448,108 | |
| 742,200 | Institution | 0.61% | 15,601,044 | |
| 637,774 | Institution | 0.53% | 13,406,009 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 7,083,310 | Institution | 5.83% | 148,891,176 | |
| 3,564,061 | Institution | 2.93% | 81,581,356 | |
| 3,006,932 | Institution | 2.48% | 63,205,711 | |
| 2,349,642 | Institution | 1.93% | 49,037,029 | |
| 1,708,015 | Institution | 1.41% | 39,096,463 | |
| 1,223,250 | Institution | 1.01% | 25,529,228 | |
| 1,022,075 | Institution | 0.84% | 21,484,017 | |
| 998,983 | Institution | 0.82% | 20,848,775 | |
| 983,077 | Institution | 0.81% | 20,664,279 | |
| 580,366 | Institution | 0.48% | 12,112,238 |
FAQ
Who Owns Catalyst Pharmaceutical Partners (CPRX)?
According to the latest TipRanks data, approximately 16.76% of the company's stock is held by institutional investors, 6.26% is held by insiders, and 34.93% is held by retail investors.
What percentage of Catalyst Pharmaceutical Partners (CPRX) stock is held by institutional investors?
According to the latest TipRanks data, approximately 16.76% of Catalyst Pharmaceutical Partners (CPRX) stock is held by institutional investors.
What percentage of Catalyst Pharmaceutical Partners (CPRX) stock is held by retail investors?
According to the latest TipRanks data, approximately 34.93% of Catalyst Pharmaceutical Partners (CPRX) stock is held by retail investors.
Who owns the most shares of Catalyst Pharmaceutical Partners (CPRX)?
iShares owns the most shares of Catalyst Pharmaceutical Partners (CPRX).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.